D-1058-2017 Class III Terminated
FDA drug recall D-1058-2017 was initiated by Teva Pharmaceuticals USA on Aug 2, 2017 and is designated Class III. Reason for recall: Failed Moisture Limits: out of specification test results for water content obtained during stability testing. The recall status is terminated (terminated Feb 28, 2018). Affected quantity: 2,880 cartons (30 unit dose blister pack per carton).
Recall details
- Product Type
- Drugs
- Report Date
- Aug 16, 2017
- Initiation Date
- Aug 2, 2017
- Termination Date
- Feb 28, 2018
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 2,880 cartons (30 unit dose blister pack per carton)
Product description
Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15
Reason for recall
Failed Moisture Limits: out of specification test results for water content obtained during stability testing.
Distribution pattern
Product distributed to OH, IL, PA, MI, VA and CT
Code information
Lot # 3138405A, Exp 8/2017
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1058-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026